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1. Introduction 
Alzheimer’s disease (AD) is a debilitating progressive neurological disease affecting 
significant number of individuals above the age of 65 years and even those who are as 
young as 30 years, around the globe. According to the Alzheimer's Association 2011 facts 
and figures report, Alzheimer’s is the sixth leading cause of death and approximately 5.4 
million people age 65 and older suffer from Alzheimer's disease in USA alone. Of all 
Americans over the age of 65, one out of every eight has AD. As the age advances, the risk of 
developing AD increases to as much as 47-50% by the age of 85. Risk is even greater if both 
parents suffer the disease (Bachman et al, 1992). Two types of AD have been described. The 
sporadic form of AD is a general deterioration of intra-neuronal contact without any 
association to any genetic element. Familial AD (FAD) on the other hand is associated with 
mutations in amyloid precursor protein (APP) on chromosome 21 (Goates A.M et al, 1991), 
apolipoprotein E gene on chromosome 19 (Cedazo-Minguez & Cowburn, 2001), presenilin 1 
(PS1) on chromosome 14 (Sudoh et al, 1998), and presenilin 2 (PS2) on chromosome 1 
(Jayadev et al, 2010). In addition, high phosphorylation that results in tangle formation is 
also attributed to mutations in the gene of microtubule associated protein Tau, located on 
chromosome 17 (Hanger et al, 1992). Among these, deposition of amyloid is widely accepted 
as the leading cause of AD. Although, amyloid plaque formation was observed in AD brains 
as early as 1907 (Alzheimer et al, 1995), it was only recently the toxicity (Yankner & Lu, 2009; 
Yankner et al, 1990) and the contents (Tokutake, 1988; Vital, 1988; Pardridge et al, 1987) have 
been established. It has been a common observation in several investigations that a single or 
multiple mutations in any of these proteins alone can affect the performance of other 
proteins resulting in neurodegeneration. Each mutation in any single protein may 
differentially affect its function. Therefore, some of the mutations have more drastic 
consequences than others such as a quintessential mutation in PS2 described by Yu (Yu et al, 
2010). In addition some of the mutations appear to cause greater harm than the others by 
shutting down a whole complex of protein activity such as specific presenilin 1 mutation 
(Heilig et al, 2010), suggesting that lethality and onset of AD is not a simple process. That 
said, the converse also appears to be true. That is, if the damage of any one of the affected 
proteins is reversed, it may be sufficient to alleviate the distress caused by the disease 
process (Kumar et al, 2000a). In light of the fact that reversal of the changes observed due to 
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or as a consequence of AD in any one or two proteins may have beneficial effects has 
opened a possibility to target these proteins to develop therapeutic agents inter alia 
(Tokutake, 1988; Vital, 1988; Pardridge et al, 1987; Lee, 2002; Morley et al, 2002; Okura & 
Matsumoto, 2007; Ohno, 2006; Schenk et al, 1999; Roggo, 2002; Evin et al, 2006; Hussain et al, 
2007; Thompson et al, 2005; Kumar et al, 2000a; Santacruz et al, 2005; Kumar et al, 2000b). 
Despite so many targets for the development of agents that may alleviate the symptoms or 
even cure the disease, the available products to treat the disease are marginal.  
Among various approaches that are made to reduce or enhance any of the affected proteins 
during AD, this chapter deals with regulating some of these proteins by antisense 
oligonucleotide technology developed in my laboratory. 
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Fig. 1. Cartoon of normal and AD brains. In AD, there is overall shrinkage of the brain and 
ventricular enlargement. Arrows indicate some changes. The morphology of AD brain itself 
suggests that the disease is more complex involving multiple factors 
2. Areas of the brain affected in AD 
There are two major changes that can be observed in the brain upon the onset of AD. The 
morphological appearance of affected brain is significantly different compared to a normal 
brain due to the shrinkage of several areas of the brain and enlargement of the ventricles 
(Fig. 1). This shrinkage of some areas and enlargement of others in AD brain are 
dramatically different from the changes in cerebral cortex of a normal brain that occur due 
to normal aging. The cerebral cortex is the outer surface of the brain. It is responsible for all 
intellectual functioning. Although we find the effect on the overall brain being affected both 
in size and biology in AD, mostly memory associated regions such as hippocampus 
(Puolivali et al, 2002), amygdala and septum show considerable degeneration in AD which 
also have shown an increased amounts of amyloid precursor protein (APP) (Kumar et al 
unpublished). Atrophy of the parietal and temporal lobes is observed in AD. Secondly, AD 
is characterized by the presence of numerous senile plaques and neurofibrillaray tangles 
www.intechopen.com
Recent Developments in Molecular Changes Leading to  
Alzheimer’s Disease and Novel Therapeutic Approaches 
 
137 
(Chen & Fernandez, 1999; Goedert & Crowther, 1989). AD is associated with disorientation, 
loss of language and memory due to these changes. The memory associated region, mostly 
hippocampus suffers a progressive neuronal dysfunction and denigration of the neurons 
(Gibson, 1987). For this reason, my laboratory concentrated on the hippocampal areas in an 
animal model of AD (Kumar et al., 1999). It has been shown that increase in hippocampal 
APP correlates with memory loss in mice that exhibit early loss of memory (Morley et al., 
2000). While the cortex, and the memory centers show physical and biochemical changes, 
the overall brain itself shows a shrinkage and enlargement of the ventricles. This may be 
due to the drastic changes in the membrane fluidity which follows the changes in the fatty 
acid composition as observed by Kumar et al (Kumar et al, 1999) in a senescence accelerated 
mouse brain. The histological features of AD in the brain are well characterized and three 
major hypotheses are currently in vogue for pharmaceutical agent development to combat 
this disease. The earliest hypothesis proposes a deficiency in cholinergic signaling. This is 
attributed to be the primary cause of initiation of the disease. The second hypothesis 
suggests that Tau protein alone or in combination with amyloid beta fragment begin the 
neuronal tangles and loss neuronal communication that initiate the disease. Thirdly APP is 
aberrantly processed resulting the plaque formation. Currently there is no clear accepted 
hypothesis for the initiation of AD. While current therapeutic agents are based on the first 
hypothesis, vigorous research to develop novel agents to combat the disease in many 
institutions, including my laboratory, is dependent on the amyloid beta hypothesis. This 
hypothesis provides several molecular targets to develop agents which may alleviate the 
disease symptoms, even though one cannot claim that they serve as preventive drug 
therapies. Therefore, it is essential to study in depth the molecular factors that are either the 
cause or manifestation of the disease to develop preventive or totally disease curing drugs. 
3. Molecular factors attributed to the manifestation of AD 
Deposition of amyloid plaques in AD patients was described as early as 1907 by Alzheimer 
–English translation (Alzheimer et al, 1995). Molecular analysis of the plaque (Pardridge et 
al, 1987) and understanding its toxicity is of recent origin (Yankner et al, 1990). The 
degeneration of neurons is attributed largely to a gradual accumulation of small molecular 
weight fragment derived from the proteolytic cleavage of APP (Blom & Linnemann, 1992). 
This peptide fragment which varies in size from 38-43 amino acids is called amyloid beta 
protein (Aß). When this fragment is less than 42 amino acids, it is considered to be soluble 
and less harmful to the neuronal communications. At 42 amino acid level it can essentially 
precipitate and form plaques with increased propensity in the brain bringing down other 
Aß fragments and disrupt the cell-cell communication consequently causing the death of the 
neurons (Suzuki et al, 1994). As Aß is obtained by the cleavage of APP by the proteases 
called the secretases, these secretases are the targets for AD therapy (Hendriksen et al, 2002; 
Citron, 2000; Dewachter & Van, 2002). These amyloid peptides are not independently 
translated although the ß-peptide region starts with an ATG codon. No independent mRNA 
for this peptide thus far is isolated that opens an investigation to study a possibility of an 
independent translation for the Aß fragment(s). Therefore, it appears that the amount of this 
peptide is dependent on the amount of APP and the rate of elimination of Aβ from the brain.  
PS1 and PS2 mutations and levels seem to affect the processing of APP thus increasing Aβ 
concentrations. We measured PS1 levels and attributed this to the increased APP processing 
to cause early loss of memory in senescence accelerated mouse (SAMP8) (Kumar et al., 2009).  
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We have also shown that one of the types of Tau increased with age in the SAMP8 mice 
(unpublished). Suppression of Tau in transgenic mice is shown to increase memory 
(Santacruz et al., 2005).  
Increased risk of AD is associated with one or both apolipoprotein, APOE e4 (Green et al., 
2002) alleles. However, the presence of APOE e4 alleles in itself is neither necessary nor 
sufficient to establish it as a diagnosis method of AD. 
4. Currently available therapies for Alzheimer's disease 
The clinical manifestation of Alzheimer’s disease (AD) is dementia that typically begins with 
subtle and poorly recognized failure of memory and slowly becomes more severe and, 
eventually, incapacitating the individual. Other common findings include confusion, poor 
judgment, language disturbance, agitation, withdrawal, and hallucinations (Bacanu et al, 
2005). Several strategies to counter these symptoms with various pharmaceutical agents are 
currently being used which essentially employ either acetylcholine esterase inhibition or 
glutamate pathway modification.  
Various approaches are currently being taken to combat AD. The "cholinergic hypothesis" 
proposes that AD is initiated by a deficiency in the production of acetylcholine (an ester of 
acetic acid and choline, CH3COOCH2CH2N(CH3). As this is an important neurotransmitter, 
early therapeutic agents were developed to increase or protect acetylcholine levels. Mode of 
action of Donepezil (commonly known as Aircept) is that it serves as an acetylcholine 
esterase inhibitor, thus acts by increasing the levels of acetylcholine. It is shown to be 
effective in mild cognitive impairments and Schizoprenia, and attention deficit disorder. 
Galantamine (commonly called Reminyl, Razadyne) is obtained from Narcissus 
pseudonarcissus, a tertiary alkaloid acts to inhibit acetyl choline esterase to increase the 
neurotransmitter, acetylcholine levels. This is a recently approved drug for AD treatment. 
Memantine is useful for many neurological disorders which includes AD. The mechanism of 
action of this drug is to act as an antagonist of the channels of N-methyl-d-aspartate 
(NMDA) receptors. The glutamate receptor subfamily is ubiquitously involved in several 
brain functions; therefore, this has a broader function for neurological disorders. The next 
available drug is rivastigmine tartrate (commonly known as Exelon) is a new generation 
acetylcholine esterase inhibitor. Lastly, tarcine (1,2,3,4-tetrahydro-5aminiacridine) is 
presumed to have several modes of actions to reverse the cognitive impairments. This is the 
earliest FDA approved drug for the treatment of AD. Its structure allows it to easily 
penetrate the cell membrane. The exact mechanism of its action is unknown. It enhances 
cholinergic function and several clinical studies with this drug have been done (Summers, 
2006; Summers et al, 1989).  
These medications, though beneficial, have not led to a cure. In all cases, they have served to 
only treat symptoms of the disease and have neither completely prevented nor reversed the 
disease. These results and other research have led to the conclusion that acetylcholine 
deficiencies may not be the direct cause but a result of neurodegeneration. Recently 
cholinergic effects have been proposed as a potential cause for the generation of the 
amyloidal plaques and tangles leading to neuroinflammation (Wenk, 2006).  
Recent techniques of developing pharmacological agents for AD depend on the amyloid 
theory. Thus, the aim of the agents generated is to reduce the amount of Aß peptide formed. 
This is achieved, at least in the animal models, either by using some plant extracts or by the 
molecular targets that reduce the amount of secretases, or APP or Tau expression. In the 
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herbal treatments, Chinese medicine leads the filed by offering several plant products for 
reducing the amyloid plaque formation. Danggui Shaoyao San (Hu et al, 2010) or Ginko biloba 
(Gold et al, 2003) are leading plant products in this area. Several large pharmaceutical 
companies are developing organic chemical agents that modulate the expression of proteins 
involved in the increase of plaque formation.  
I will describe our approach that uses antisense oligonucleotide technology to achieve the 
same goal of prevention of plaque formation by reducing the amount of amyloid produced. 
This chapter essentially is dedicated to the approaches for the regulation of amyloid 
precursor protein (APP) and the proteases that generate plaque forming small molecular 
beta protein (Aß) using antisense oligonucleotides to specific regions of relevant mRNA(s) 
designed in my laboratory. Further, I will also describe a novel hybrid antisense technique 
which might open a new approach to regulate more than one message with a single 
antisense oligonucleotide. These hybrid antisense oligonucleotides have also been tested by 
my collaborators who confirmed their efficacy in animal models.  
5. Molecular techniques to counter the factors that induce AD symptoms 
At molecular level, several targets have been identified to develop new drugs. The approach 
of the large pharmaceutical agencies is to inhibit γ secretase (Eli Lilly, Merk), blocking 
Receptor for advanced glycation end products (RAGE-by Pfizer), beta secretase-1 block 
(CoMentis pharma), 5-HT1A receptor antagonish development (Wyeth etc labs) in addition 
to immunization against Aß protein (Melnikova, 2007).  
 In my laboratory we have altered the levels of APP, Tau PS1, γ and β secretases which have 
direct or indirect role in the generation of insoluble plaque forming Aβ42 by using antisense 
oligonucleotide and siRNA technologies. We have shown their potency and beneficial 
effects in the cell culture and as well as animal models. We have successfully reversed the 
symptoms of memory loss and behavioral alterations (Banks et al, 2000; Kumar et al, 2000a). 
Even by reducing the levels of just APP, improvement to memory have been observed.  
Recently we also developed what is named as hybrid antisense technology (unpublished) 
which has successfully affected more than one protein at molecular level. This novel 
technology will open new methods to possible successful therapies not only for AD but also 
other diseases, neurological or otherwise, which involves more than one gene. 
6. Antisense nucleotide technology 
Gene regulation can be achieved by several methods. Among these, ribozyme (Macpherson 
et al, 1999), small molecular weight interfering RNAs (siRNA/RNAi) (Koutsilieri et al, 2007) 
and antisense oligonucleotide technologies (Helene & Toulme, 1990; Toulme et al, 1990) have 
been extensively studied. These techniques use a relatively simple concept that a 
complementary sequence can make a Watson-Crick base pairing with corresponding 
message thus preventing the translation. In the case of ribozyme which has a clover leaf 
structure, called as hammer head or hair pin, seeks out the targeted mRNA using 
complementary sequences, binds to mRNA and cleaves it, acting as a nuclease. RNA 
interference by SiRNAs and miRNAs are more complex. A dicer generates a double 
stranded structure of 21-23 nucleotides in length which gets separated and the 
complementary strand is amplified by RdRP (RNA dependent RNA polymerase). The single 
strand complexes with RISC (RNA induced silencing complex) and binds to target 
www.intechopen.com
 
Advanced Understanding of Neurodegenerative Diseases 
 
140 
sequences and cleaves the mRNA which gets inactivated. Although the ribozyme and RNAi 
technologies are powerful techniques, their utility is largely confined to cell culture and in 
vitro studies due to the difficulties in their transport to specific sites without nuclease 
induced degradation. Antisense oligonucleotide technology on the other hand has more 
flexibility for regulation of messages both in vitro and in vivo. This technique utilizes a set of 
complementary oligonucleotides to a specific mRNA, to block its translation. The use of 
complementary deoxyribonucleotide sequences to halt mRNA translation has been 
described as early as 1977 (Paterson et al, 1977). In fact we have shown around the same time 
that RNA molecules and oligonucleotides could prevent RNA transcription in vitro (Kumar 
et al, 1977). Simplest method by which complementary sequences bind to a segment of a 
given mRNA block the translation of the mRNA is given in fig. 2. The mechanism of action 
of an antisense oligonucleotide is generally by RNase H cleavage of the double stranded 
region created by the complementary oligonucleotide that forms a hybrid with specific 
sequences on the mRNA. RNase H is rather ubiquitous enzyme. Alternatively, the hybrid 
formed by the complementary oligonucleotide may serve as a block to ribosome from 
proceeding to complete peptide synthesis. If the complementary sequences are made to 5’ 
un-translated region near or on the ribosome binding site, the ribosome would not even 
bind to initiate the translation or can be halted from movement. However, an internal 
antisense oligonucleotide generally works by RNase H mechanism, as assessed by the 
detection of incomplete mRNA molecules. Antisense oligonucleotide technology is not 
limited to preventing translation, but can be used to target the gene itself and prevent 
mRNA transcription thus preventing RNA splicing itself. 
 
 
Fig. 2. A cartoon of complementary sequence (antisense) blockade of mRNA translation. 
This cartoon shows the steric hindrance of to the ribosome to prevent further completion of 
protein translation 
There are several advantages in using antisense technology as opposed to RNAi technology. 
First of all, the antisense oligonucleotides are deoxy oligonucleotides, therefore, are more 
stable than RNA based antisense as in RNAi technology which uses ribonucleotide 
backbone in the complementary sequences. Therefore, it is more vulnerable to RNases. 
Secondly, the phosphate back bone and deoxyribose sugar can be modified in the antisense 
technology as these are made synthetically. This is done by substituting various other 
groups (Fig. 3) making the oligonucleotide more resistant to deoxyribonucleases. Thirdly, 
the quantity of antisense oligonucleotide can be manipulated so that the extent of mRNA 
regulation can be controlled. Further, sequences selected on the target mRNA, also give a 
handle to modulate the mRNA translation. In the case of RNA interference, such controls 
cannot be exerted. In the RNAi technology, the complementary sequences along with coding 
sequences need to be cloned into a vector, which generates the double stranded molecules 
continuously. Further, the double stranded molecule needs to be converted to single strand 
by cellular machinery to generate the antisense molecules which in turn inactivate the 
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targeted message (Moazed, 2009). For all practical purposes, using deoxyoligonucleotides 
with altered sugar or phosphate bone appear to be more practical to modulate messages 
than SiRNA/RNAi techniques which have the same goal. However, the latter ones which 
have been shown to be more effective in cell cultures may become potent therapeutic agents 
once techniques to regulate their expression are developed. Currently, in a whole animal, 
including man, oligonucleotide technology may be more manageable to modulate gene 
activity. I generally used phophorothiated antisense oligonucleotides for in vivo studies (in 
the animal and cells) successfully (Kumar et al, 2000c; Kumar et al, 2001). We have shown 
that phosphorothiated antisense molecules did reverse the memory loss caused by aging or 
amyloid accumulation. Further, many laboratories used this technology against cancer 
(Dolnick, 1991), amyotrophic lateral sclerosis (ALS) (Smith et al, 2006), Ebola (Swenson et al, 
2009; Enterlein et al, 2006), HIV Aids (Stein et al, 1989; Matsukura et al, 1989; Rossi et al, 
2007), diabetes (Machen et al, 2004), Duchenne muscular dystrophy (Bremmer-Bout et al, 
2004; Aartsma-Rus et al, 2004), Asthma (Nyce & Metzger, 1997) etc. This technique has been 
applied for a variety of diseases including neurological diseases.  
 
 
Fig. 3. Substitutions that make the oligonucleotides resistant to nuclease degradation. Figure 
shows currently available base substitutions that confer resistance to nuclease resistance to 
the oligonucleotide backbone 
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7. Uptake of antisense oligonucleotides  
Antisense oligonucleotides are easily taken up into the eukaryotic cells across cell 
membrane by active transport which is temperature dependent (Loke et al, 1989). However, 
the transport into neuronal cells is not a passive transport and needs help with external 
agents. Fig. 4 shows various agents that we used for transport across PC 12 cell line to test 
the efficacy of antisense oligonucleotides. In this experiments a 42 mer antisense against 
human APP. Amphotericin B was first used by us to transport DNA (Kumar et al, 1974) and 
later shown to be a valuable agent for the transport of oligonucleotides into 3T3 cells 
(Garcia-Chaumont et al, 2000). Using CaCl2 or Amphotericin B would cause some cell death 
if we cross concentrations above 1mM and 10 µM respectively. In the figure we have used 
lower than these concentrations. DMSO concentration was 1%. Lipid encapsulation 
transporter, lipofectamine did not cause any cell damage even at concentrations higher than 
suggested by the manufacturer.  
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Fig. 4. Efficiency of transport of a 42 mer oligonucleotide into HTB 11 cells in the presence of 
various agents. The oligonucleotide was labeled with 32P and purified by ethanol 
precipitation and tested for homogeneity on a 15% polyacrylamide gel. The cells were 
incubated with known amount of labeled oligonucleotide for specified times, washed, 
homogenized and counted. Notice that minimal concentrations of CaCl2 in combination 
with DMSO or Amphotericin B are of great advantage in the transport of oligonucleotides 
When a mouse is administered an antisense oligonucleotide by any route, it can reduce the 
translation of corresponding mRNA. In the animal system, the neuronal cells have the 
ability to transport the oligonucleotide without the additional aid by cationic reagents. 
However, in both neuronal cells in culture and in the animal, the transport of 
oligonucleotide occurs by binding to specific receptor(s). When the cells were incubated 
with 32P labeled oligonucleotide in the presence of DMSO+CaCl2 as in fig. 5 and cell 
extracts were subjected gel retardation assay (Scott et al, 1994) by 12% polyacrylamide gel, 
we observed higher size bands suggesting its association with a protein(s) which may serve 
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as receptors to transport the oligonucleotide (Fig. 5). Such an association is observed in the 
brain tissues of the animals which were administered the oligonucleotide. We have noticed 
that there are receptors in the brain that may be facilitating the transport of 
oligonucleotides.  
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Oligo associated
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Fig. 5. Association of oligonucleotide with cellular receptor protein. HTB 11 human 
neuronal cells were incubated for 60 minutes and the cell extracts were run on 12% 
polyacrylamide gels in Trisborate buffer and subjected to autoradiography. Notice the 
association of majority of oligonucleotide with protein(s)  
In the case of animals, the delivery of antisense oligonucleotides by three routes was tested. 
When the delivery was made by icv (intra crebrovascular), minimum amounts (as low as 60 
ng/antisense oligonucleotides of 20-40 nucleotides) was very effective in reversing the loss 
of memory or acquisition. This is because most of the antisense oligonucleotide could be 
targeted to hippocampal area which is involved in memory. When an antisense 
oligonucleotide made against some sequences at Aβ region of APP (5’ 
GGCGCCTTTGTTCGAACCCACATCTTCAGCAAAGAACACCAG – Kumar-US patent 
6310048-2001) was administered by icv, its levels were considerably reduced (Kumar et al, 
2000b). The transport of oligonucleotide though to a lesser extent occurs also by iv (intra 
venous) and reverses memory loss in mice (Banks et al, 2000). The transport into brain could 
also be achieved by oral or peritoneal routes (Kumar unpublished). For therapy, oral 
administration is most preferred. The distribution of orally and intraperitoneally 
administered oligonucleotide of 42 nucleotides is given in Figs. 6 and 7 respectively. Notice 
that by both routes of administration the percentage of the administered oligonucleotide 
recovered in the brain is same. But the distribution of the oligonucleotide in various organs 
is different. The behavioral studies are yet to be performed to quantify the efficacy of the 
oral or intraperitoneal administrations. But, the stability of the oligonucleotide was tested by 
extracting the oligonucleotide from these tissues by polyacrylamide gels. The 
oligonucleotide does undergo some degradation in all the tissues in spite of the fact that the 
oligonucleotide was phosphorothiated. However, what was extracted from brain did not 
seem to be degraded and is associated with a protein as it runs at a higher molecular weight 
than the monomer on polyacrylamide gels. 
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Fig. 6. Distribution short (20 mer-panel A) and long (42 mer-panel B) 32P-labled 
oligonucleotide 4hrs after oral administration in C57 black mice. 6 month old C57 black mice 
were administrated 32P-labled oligonucleotides and their distribution is similar irrespective 
of the size of the oligonucleotide 
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Fig. 7. Distribution short (20 mer-panel A) and long (42 mer-panel B) 32P-labled 
oligonucleotide 4hrs after intraperitoeneal administration in C57 black mice. 6 month old C57 
black mice were administrated 32P-labled oligonucleotides and their distribution was 
determinated as percent of a total/mg of protein. The distribution is similar irrespective of 
the size of the oligonucleotide 
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If antisense oligonucleotides have become effective therapeutic agents, the efficacies of 
administration by different routes have to be established. Although, there is no evidence for 
any adverse effect in animal models used, in humans more experiments have to be 
performed to confirm that there will be no adverse effect. As oligonucleotides are natural 
products, adverse effects if any are likely to be minimal, if oral, nasal or intraperitoneal are 
the routes of administration. 
8. New antisense oligonucleotide technology to regulate multiple genes 
products with a single oligonucleotide 
Variety of neurological diseases including AD, involve altered transcriptional and 
translational processes of more than one gene. If we consider Alzheimer’s disease, a direct 
linkage exists for disease manifestation and altered expression of secretases, APP, 
apolipoprotein E, presenilins 1 and 2 and Tau phosphorylation. The changes in the 
expression of so many genes may be due to a single or multiple mutations in the 
corresponding genes or due to onset of disease. Therefore, these gene products are the 
rational molecular targets for the development of therapeutic agents. The results obtained 
by antisense molecules developed in my laboratory that modulated the expression of some 
of these proteins showed that this technology may be used to down regulate the specific 
mRNAs both in vivo and in vitro with surprisingly positive out come. In the case of 
methionine enkephalin, we have successfully used more than one antisense molecule to 
regulate the levels of this protein, as this protein has repetitive sequences (Banks et al, 2004). 
However, when two or more antisense oligonucleotides are used to regulate the messages, 
there is a high probability of developing anti nucleic acid antibodies (Isenberg et al, 
2007;Hahn, 1998). In order to avoid such possibility, a technique where one single antisense 
oligonucleotide molecule can down regulate more than one mRNA is developed in my 
laboratory. It has been shown that even hexa and decamers have the ability to down 
regulate a targeted mRNA (Wagner, 1994;Wagner, 1995). Thus two phosphorothiated 
antisense oligonucleotides of ten nucleotide lengths against PS1 (5’TCTCTGTCAT) and APP 
(5’TGGGCAGCAT) mRNAs were constructed. A random oligonucleotide 
(5’GATCACGTAC) was used as control. Their ability to down regulate APP and PS1 
proteins in COS 7 cells transfected with respective cDNAs in a co-transfected cell system 
was tested (Fig. 8, 9). Immunoblotting technique was used to quantify the expression 
(Kumar et al, 2009). In each of these cases there is 40-50% reduction in protein expression.  
Based on the above observation A 20 mer hybrid antisense molecule was constructed with a 
combined sequence of anti APP (blue) and anti PS1 (Purple) (5’ 
TGGGCAGCATTCTCTGTCAT). The hybrid consists of the first ten nucleotides are anti to 
APP message and the next ten are to anti to PS1 message. The fist 10 nucleotides, when 
binding to APP mRNA, there will be a 5’ over hang of 10 nucleotides and when it is binding 
to PS1 mRNA, it will have a 3’ over hang of the 10 nucleotides. Theoretically, such an over 
hang need not weaken the antisense blockade or RNase H degradation of the mRNA 
preventing it from translation. Random oligonucleotide (5’GATCACGTACACATCGACAC) 
along with the hybrid antisense described above was tested in a COS 7 cell transfected with 
the APP and PS1 cDNAs. The hybrid antisense molecule could effectively reduce the 
expression of both APP and PS1 almost as efficiently as individual 10 mers (Fig. 10) in 24 
hours. The hybrid antisense oligonucleotides were successfully used in the animals to 
reverse the loss of memory in animal models of AD (Kumar et al unpublished). 
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Fig. 8. Down regulation of PS1 with a 10 nucleotide antisense oligonucleotide in COS 7 cells. 
COS 7 cells were transfected with PS1 cDNA in pCDNA expression vector and a 10 mer 
antisense or a random oligonucleotide was co-transfected. Cells were grown for 24 hrs and 
the 10 µg of protein was subjected to immunoblotting. Lower panel gives band densities 
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Fig. 9. Down regulation of APP with a 10 nucleotide antisense oligonucleotide in COS 7 cells. 
COS 7 cells were transfected with APP cDNA in pCDNA expression vector and a 10 mer 
antisense or random oligonucleotide was co-transfected. Cells were grown for 24 hrs and 
the 10 µg of protein was subjected to immunoblotting. Lower panel gives band densities 
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Using a single antisense oligonucleotide molecule containing antisense sequences to two 
mRNAs to down regulate both mRNAs at the same time may have an advantage in 
avoiding possible auto antibody induction that may be caused if two different antisense 
molecules are administered at the same time. We have further extended this technique by 
using an oligonucleotide which has antisense oligonucleotide sequences against three 
mRNAs (PS1, APP and Tau).  
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Fig. 10. Down regulation of APP and PS1 mRNAs by a hybrid antisense oligonucleotide. 
COS7 cells transfected with cDNAs of APP and PS1 were co-transfected with hybrid 
antisense oligonucleotide and a random control of 20 nucleotides. 24hrs after transfection, 
10 μg of cell extracts were subjected to immunoblotting. Notice the reduction of protein 
expression in antisense transfected cells 
Despite the fact that the antisense sequence for one of the messages is embedded in the 
middle of the oligonucleotide the tribrid antisense molecule thus generated down regulated 
the translational products of all the three targeted messages (data not given). This approach 
of one oligonucleotide to regulate multiple messages may serve as an invaluable tool in 
antisense technology. This would also offset the fear of developing autoimmunity.  
9. Conclusion 
The use of complementary oligonucleotides to prevent translation of a given message was 
described as early as 1977 (Paterson et al, 1977). Using small RNA or oligonucleotides to 
block transcription by RNA polymerases was described by Kumar et al in 1977 (Kumar et al, 
1977). Popular use of complementary synthetic deoxyribonucleitides took another 20 plus 
years. For a variety of reasons such as the low cost synthesis of oligonucleotides, relative 
stability, ease of transport, reproducible down regulation of a specific message, relatively 
simple method for base modification to generate nuclease resistant backbone etc. made 
antisense technology against a disease state became more common. Extensive use of 
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antisense oligonucleotides in a variety of diseases is not therapeutically ubiquitous after the 
advent of more powerful RNA interference technology. Various methods are being 
developed to achieve a viable transport of SiRNA, miRNA (micro RNA) or ShRNA (short 
hairpin RNA) for clinical use (Leng et al, 2009). In this technology also, to increase the 
stability of interfering RNAs, base modifications such as 2’-O-methyl or morpholino are 
being developed (Behlke, 2008;Robbins et al, 2009). Despite increasing the stability, and 
billions of dollars spent to develop the agents to down regulate mRNAs by RNA 
interference, still a targeted and controlled delivery of SiRNA is a far cry. In addition, a 
viral/bacterial vector usage, while attractive, regulation of the amount produced is difficult. 
Therefore, currently complementary oligonucleotide therapy is an attractive practical 
method.  
In this article, a novel method is proposed where by more than one gene product may be 
regulated by a single complementary sequence is described. This procedure is a valuable 
tool in combating diseases where more than one gene product is shown to be affected due to 
disease manifestation or as the cause for the disease. This technique will be of great use due 
to the fact that possible autoimmunity against DNA will be less compared to administering 
more than one antisense oligonucleotide. It is possible to envisage that this hybrid 
technology be combined with the currently available SiRNA technology for effective down 
regulation of several messages at the same time. My laboratory is currently developing such 
possible products. Novel oligonucleotides that enhance one gene and reduce another are 
also being developed in my laboratory. Such structures will naturally have a tremendous 
potential as therapeutic agents, as any disease state is not only accompanied by over 
expression, but also involves decreased expression of one or more mRNAs. As for the 
delivery of such molecules in humans, I would suggest nasal delivery instead of oral, 
intravenous or intra peritoneal. Results of such delivery using an animal model is not 
presented here, but that route appeared be very effective in preliminary experiments. As 
oligonucleotides may be considered natural to the biological systems, the possible side 
effects by antisense delivery may be expected to be rather insignificant. In conclusion, 
although RNA interference by small molecular weight or micro RNA and ShRNA is of great 
importance, direct antisense oligonucleotide technology should not be completely ignored, 
particularly because of its simplicity and ease with which such interfering molecules can be 
synthesized and administered for relatively low cost. Further, the demand from the cellular 
machinery by synthetic oligonucleotide for their processing is minimal compared to RNA 
interference technology which requires dicer mechanism. A combinational therapy of RNA 
interference and the hybrid technology may also be speculated for an efficient therapeutic 
intervention of over/under produced transcription and translational products. Such 
molecules are contemplated and designed by me in my laboratory. A note in proof: Craft et 
al (Archives of neurology on line Sep. 2011) reported an effective intranasal insulin therapy 
for AD and mild cognitive impairments, which further suggests that nasal administration 
suggested in this article may be the ideal route of administration for neurological 
impairments. 
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